{"id":56671,"date":"2026-02-09T21:04:53","date_gmt":"2026-02-09T13:04:53","guid":{"rendered":"https:\/\/flcube.com\/?p=56671"},"modified":"2026-02-09T21:04:54","modified_gmt":"2026-02-09T13:04:54","slug":"pfizers-hympavzi-wins-fda-priority-review-for-pediatric-hemophilia-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56671","title":{"rendered":"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion"},"content":{"rendered":"\n<p><strong>Pfizer Inc.<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a><\/strong>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has <strong>accepted for priority review<\/strong> its <strong>supplemental Biologics License Application (sBLA)<\/strong> for <strong>Hympavzi (marstacimab)<\/strong>, seeking approval to treat <strong>hemophilia A or B patients aged 6 years and older with inhibitors<\/strong>, as well as <strong>children aged 6-11 without inhibitors<\/strong>. The expansion would significantly broaden access to the <strong>first non-factor hemophilia therapy<\/strong> targeting <strong>tissue factor pathway inhibitor (TFPI)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Pfizer Inc. (NYSE: PFE)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Hympavzi (marstacimab) \u2013 anti-TFPI monoclonal antibody<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>Supplemental Biologics License Application (sBLA)<\/td><\/tr><tr><td><strong>Review Status<\/strong><\/td><td>Priority review granted<\/td><\/tr><tr><td><strong>Current Approval<\/strong><\/td><td>Ages 12+ with hemophilia A\/B without inhibitors (US, 2024)<\/td><\/tr><tr><td><strong>Requested Expansion<\/strong><\/td><td>Ages 6+ with inhibitors; ages 6-11 without inhibitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-amp-mechanism-of-action\">Technology Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class:<\/strong> <strong>Non-factor replacement therapy<\/strong> \u2013 First\u2011in\u2011class hemophilia treatment not requiring clotting factor VIII or IX administration<\/li>\n\n\n\n<li><strong>Novel Mechanism:<\/strong> <strong>&#8220;Coagulation rebalancing by targeting TFPI&#8221;<\/strong><\/li>\n\n\n\n<li>Marstacimab binds <strong>tissue factor pathway inhibitor (TFPI)<\/strong>, blocking its anticoagulant function<\/li>\n\n\n\n<li>Restores <strong>thrombin generation potential<\/strong> without exogenous factor replacement<\/li>\n\n\n\n<li><strong>Administration:<\/strong> <strong>Fixed-dose, once-weekly subcutaneous injection<\/strong> \u2013 Eliminates need for intravenous infusions and enables home administration<\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> Addresses <strong>inhibitor patients<\/strong> who cannot receive standard factor replacement due to neutralizing antibodies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-populations-amp-unmet-need\">Target Populations &amp; Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Patient Segment<\/th><th>Current Standard of Care<\/th><th>Marstacimab Value Proposition<\/th><\/tr><\/thead><tbody><tr><td><strong>Hemophilia A\/B with inhibitors (ages 6+)<\/strong><\/td><td>Bypassing agents (e.g., FEIBA, NovoSeven) \u2013 expensive, frequent IV<\/td><td>Weekly SC injection with predictable hemostasis<\/td><\/tr><tr><td><strong>Hemophilia A\/B without inhibitors (ages 6-11)<\/strong><\/td><td>Factor VIII\/IX prophylaxis \u2013 burden of frequent infusions<\/td><td>Reduced treatment burden, improved adherence<\/td><\/tr><tr><td><strong>Young children (6-11)<\/strong><\/td><td>Limited non-factor options; invasive administration challenges<\/td><td>Age-appropriate subcutaneous delivery<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-positioning\">Market Context &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hemophilia Market Scale:<\/strong> Global hemophilia therapeutics market exceeds <strong>$15 billion<\/strong>, with <strong>inhibitor patients<\/strong> representing <strong>30% of severe hemophilia A cases<\/strong> and historically underserved by conventional prophylaxis.<\/li>\n\n\n\n<li><strong>Non-Factor Disruption:<\/strong> Marstacimab\u2019s <strong>TFPI-targeting mechanism<\/strong> positions Pfizer to <strong>disrupt factor replacement dominance<\/strong>, competing with <strong>Genevant\/Alnylam\u2019s fitusiran (RNAi)<\/strong> and <strong>Sanofi\u2019s efanesoctocog alfa (factor VIII fusion)<\/strong> in the hemophilia innovation race.<\/li>\n\n\n\n<li><strong>Pediatric Expansion Value:<\/strong> <strong>Priority review for ages 6-11<\/strong> captures <strong>prophylaxis initiation window<\/strong>, potentially establishing lifelong therapy loyalty before patients transition to adult factor regimens.<\/li>\n\n\n\n<li><strong>Inhibitor Market Penetration:<\/strong> Approval for <strong>inhibitor patients<\/strong> would unlock the <strong>highest-unmet-need hemophilia segment<\/strong>, where annual treatment costs often exceed <strong>$1 million per patient<\/strong> and clinical outcomes remain suboptimal.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Milestone<\/th><th>Anticipated Timing<\/th><\/tr><\/thead><tbody><tr><td><strong>Current<\/strong><\/td><td>FDA priority review for sBLA (ages 6+ with inhibitors; 6-11 without)<\/td><td>Q1 2026<\/td><\/tr><tr><td><strong>Near-term<\/strong><\/td><td>PDUFA decision date (priority review = 6-month timeline)<\/td><td>Q3 2026<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>EU EMA and Japan PMDA submissions for pediatric indications<\/td><td>2026-2027<\/td><\/tr><tr><td><strong>Future<\/strong><\/td><td>Real-world evidence generation in youngest children (under 6)<\/td><td>Post-approval studies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Hympavzi regulatory approval timelines, pediatric hemophilia market penetration, and competitive positioning in the non-factor therapy space. Actual results may differ due to FDA review outcomes, pricing negotiations with payers, and competitive responses from factor replacement and gene therapy manufacturers.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56672,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[38,863,309,24],"class_list":["post-56671","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-market-approval-filings","tag-nyse-pfe","tag-pfizer","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Hympavzi (marstacimab), seeking approval to treat hemophilia A or B patients aged 6 years and older with inhibitors, as well as children aged 6-11 without inhibitors. The expansion would significantly broaden access to the first non-factor hemophilia therapy targeting tissue factor pathway inhibitor (TFPI).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56671\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Hympavzi (marstacimab), seeking approval to treat hemophilia A or B patients aged 6 years and older with inhibitors, as well as children aged 6-11 without inhibitors. The expansion would significantly broaden access to the first non-factor hemophilia therapy targeting tissue factor pathway inhibitor (TFPI).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56671\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T13:04:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-09T13:04:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0903.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56671#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56671\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion\",\"datePublished\":\"2026-02-09T13:04:53+00:00\",\"dateModified\":\"2026-02-09T13:04:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56671\"},\"wordCount\":494,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56671#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0903.webp\",\"keywords\":[\"Market approval filings\",\"NYSE: PFE\",\"Pfizer\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56671#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56671\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56671\",\"name\":\"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56671#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56671#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0903.webp\",\"datePublished\":\"2026-02-09T13:04:53+00:00\",\"dateModified\":\"2026-02-09T13:04:54+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Hympavzi (marstacimab), seeking approval to treat hemophilia A or B patients aged 6 years and older with inhibitors, as well as children aged 6-11 without inhibitors. The expansion would significantly broaden access to the first non-factor hemophilia therapy targeting tissue factor pathway inhibitor (TFPI).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56671#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56671\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56671#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0903.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0903.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56671#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Hympavzi (marstacimab), seeking approval to treat hemophilia A or B patients aged 6 years and older with inhibitors, as well as children aged 6-11 without inhibitors. The expansion would significantly broaden access to the first non-factor hemophilia therapy targeting tissue factor pathway inhibitor (TFPI).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56671","og_locale":"en_US","og_type":"article","og_title":"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion","og_description":"Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Hympavzi (marstacimab), seeking approval to treat hemophilia A or B patients aged 6 years and older with inhibitors, as well as children aged 6-11 without inhibitors. The expansion would significantly broaden access to the first non-factor hemophilia therapy targeting tissue factor pathway inhibitor (TFPI).","og_url":"https:\/\/flcube.com\/?p=56671","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-09T13:04:53+00:00","article_modified_time":"2026-02-09T13:04:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0903.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56671#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56671"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion","datePublished":"2026-02-09T13:04:53+00:00","dateModified":"2026-02-09T13:04:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56671"},"wordCount":494,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56671#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0903.webp","keywords":["Market approval filings","NYSE: PFE","Pfizer","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56671#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56671","url":"https:\/\/flcube.com\/?p=56671","name":"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56671#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56671#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0903.webp","datePublished":"2026-02-09T13:04:53+00:00","dateModified":"2026-02-09T13:04:54+00:00","description":"Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Hympavzi (marstacimab), seeking approval to treat hemophilia A or B patients aged 6 years and older with inhibitors, as well as children aged 6-11 without inhibitors. The expansion would significantly broaden access to the first non-factor hemophilia therapy targeting tissue factor pathway inhibitor (TFPI).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56671#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56671"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56671#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0903.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0903.webp","width":1080,"height":608,"caption":"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56671#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer\u2019s Hympavzi Wins FDA Priority Review for Pediatric Hemophilia Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0903.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56671"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56671\/revisions"}],"predecessor-version":[{"id":56673,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56671\/revisions\/56673"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56672"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56671"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56671"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}